-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Hematologic Toxicity of CAR-T

Program: Education Program
Session: Hematologic Toxicity of Immunotherapies
Saturday, December 9, 2023, 4:00 PM-5:15 PM

Frederick L. Locke, MD

Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL

Disclosures: Locke: Allogene: Consultancy, Other: Institutional ; Amgen: Consultancy; bluebird bio: Consultancy, Other: Institutional ; BMS/Celgene: Consultancy, Other: Institutional ; Calibr: Consultancy; Caribou: Consultancy; Cellular Biomedicine Group: Consultancy; EcoR1: Consultancy; Cowen: Consultancy; Daiichi Sankyo: Consultancy; Novartis: Consultancy, Other: Institutional ; Sana: Consultancy; Takeda: Consultancy; Clinical Care Options Oncology: Other; A2: Consultancy, Other: Travel support; Emerging Therapy Solutions: Consultancy; National Cancer Institute: Other: Institutional ; GammaDelta Therapeutics: Consultancy; Gerson Lehrman Group (GLG): Consultancy; Iovance: Consultancy; Kite, a Gilead Company: Consultancy, Other: Institutional ; Individual Patents: Patents & Royalties: Several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy; Umoja: Consultancy; Aptitude Health: Other; Wugen: Consultancy; Janssen: Consultancy; Imedex: Other; ASH: Other; BioPharma Communications CARE Education: Other; CERo Therapeutics: Other: Institutional; Legend Biotech: Consultancy; Leukemia and Lymphoma Society: Other: Institutional ; Society for Immunotherapy of Cancer: Other: Institutional .

Previous Presentation | Next Presentation >>